Vasodilator Effect of Glucagon: Receptorial Crosstalk Among Glucagon, GLP-1, and Receptor for Glucagon and GLP-1

被引:21
作者
Selley, E. [1 ,2 ]
Kun, S. [1 ,2 ]
Szijarto, I. A. [3 ,4 ]
Kertesz, M. [1 ,2 ]
Wittmann, I. [1 ,2 ]
Molnar, G. A. [1 ,2 ]
机构
[1] Univ Pecs, Dept Med 2, Pecs, Hungary
[2] Univ Pecs, Nephrol Ctr, Pecs, Hungary
[3] Charite Campus Virchow Klinikum, Med Clin Nephrol & Internal Intens Care, Berlin, Germany
[4] Max Delbruck Ctr Mol Med, ECRC, Berlin, Germany
关键词
aortic rings; glucagon; GLP-1; vasodilatation; INSULIN-INDUCED RELAXATION; SMOOTH-MUSCLE-CELLS; FATTY LIVER-DISEASE; ANTIDIABETIC AGENTS; MECHANISM; ARTERIES; SECRETION; CHANNELS; INCREASE; INJURY;
D O I
10.1055/s-0042-101794
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glucagon is known for its insulin-antagonist effect in the blood glucose homeostasis, while it also reduces vascular resistance. The mechanism of the vasoactive effect of glucagon has not been studied before; thereby we aimed to investigate the mediators involved in the vasodilatation induced by glucagon. The vasoactive effect of glucagon, insulin, and glucagon-like peptide-1 was studied on isolated rat thoracic aortic rings using a wire myograph. To investigate the mechanism of the vasodilatation caused by glucagon, we determined the role of the receptor for glucagon and the receptor for GLP-1, and studied also the effect of various inhibitors of gasotransmitters, inhibitors of reactive oxygen species formation, NADPH oxidase, prostaglandin synthesis, protein kinases, potassium channels, and an inhibitor of the Na+/Ca2+-exchanger. Glucagon causes dose-dependent relaxation in the rat thoracic aorta, which is as potent as that of insulin but greater than that of GLP-1 (7-36) amide. Vasodilatation by GLP-1 is partially mediated by the glucagon receptor. The vasodilatation due to glucagon evokes via the glucagon-receptor, but also via the receptor for GLP-1, and it is endothelium-independent. Contribution of gasotransmitters, prostaglandins, the NADPH oxidase enzyme, free radicals, potassium channels, and the Na+/Ca2+ -exchanger is also significant. Glucagon causes dose-dependent relaxation of rat thoracic aorta in vitro, via the receptor for glucagon and the receptor for GLP-1, while the vasodilatation evoked by GLP-1 also evolves partially via the receptor for glucagon, thereby, a possible crosstalk between the 2 hormones and receptors could occur.
引用
收藏
页码:476 / 483
页数:8
相关论文
共 50 条
  • [41] Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males
    Zilstorff, Dorte B.
    Richter, Michael M.
    Hannibal, Jens
    Jorgensen, Henrik L.
    Sennels, Henriette P.
    Wewer Albrechtsen, Nicolai J.
    BMC ENDOCRINE DISORDERS, 2024, 24 (01)
  • [42] Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
    Hope, David C. D.
    Vincent, Matthew L.
    Tan, Tricia M. M.
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [43] Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males
    Dorte B. Zilstorff
    Michael M. Richter
    Jens Hannibal
    Henrik L. Jørgensen
    Henriette P. Sennels
    Nicolai J. Wewer Albrechtsen
    BMC Endocrine Disorders, 24
  • [44] Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of and Diabetes
    Palani, Anandan
    Nawrocki, Andrea R.
    Orvieto, Federica
    Bianchi, Elisabetta
    Mandic, Emanuela
    Pessi, Antonello
    Huang, Chunhui
    Deng, Qiaolin
    Toussaint, Nathalie
    Walsh, Erika
    Reddy, Vijay
    Ashley, Eric
    He, Huaibing
    Mumick, Sheena
    Hawes, Brian
    Marsh, Donald
    Erion, Mark
    Nargund, Ravi
    Carrington, Paul E.
    ACS MEDICINAL CHEMISTRY LETTERS, 2022, 13 (08): : 1248 - 1254
  • [45] Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease
    Simsir, Ilgin Yildirim
    Soyaltin, Utku Erdem
    Cetinkalp, Sevki
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2018, 12 (03) : 469 - 475
  • [46] Absence of Glucagon and Insulin Action Reveals a Role for the GLP-1 Receptor in Endogenous Glucose Production
    Jun, Lucy S.
    Millican, Rohn L.
    Hawkins, Eric D.
    Konkol, Debra L.
    Showalter, Aaron D.
    Christe, Michael E.
    Michael, M. Dodson
    Sloop, Kyle W.
    DIABETES, 2015, 64 (03) : 819 - 827
  • [47] Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates
    Knerr, Patrick J.
    Mowery, Stephanie A.
    Finan, Brian
    Perez-Tilve, Diego
    Tschoep, Matthias H.
    DiMarchi, Richard D.
    PEPTIDES, 2020, 125
  • [48] Glucose kinetics: an update and novel insights into its regulation by glucagon and GLP-1
    Gastaldelli, Amalia
    Gaggini, Melania
    DeFronzo, Ralph
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2017, 20 (04) : 300 - 309
  • [49] The endocrine disrupting potential of monosodium glutamate (MSG) on secretion of the glucagon-like peptide-1 (GLP-1) gut hormone and GLP-1 receptor interaction
    Shannon, Maeve
    Green, Brian
    Willars, Gary
    Wilson, Jodie
    Matthews, Natalie
    Lamb, Joanna
    Gillespie, Anna
    Connolly, Lisa
    TOXICOLOGY LETTERS, 2017, 265 : 97 - 105
  • [50] Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes
    Lang, Shan
    Yang, Jin
    Yang, Kun
    Gu, Liangbiao
    Cui, Xiaona
    Wei, Tianjiao
    Liu, Junling
    Le, Yunyi
    Wang, Haining
    Wei, Rui
    Hong, Tianpei
    BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (01)